SLU Researcher Finds Help for Alzheimer's-Associated Agitation with New FDA-Approved Treatment
ST. LOUIS – A Saint Louis University researcher was instrumental in developing the first and only Food and Drug Administration (FDA) approved treatment for agitation associated with Alzheimer’s dementia.
In a paper published in JAMA Neurology, senior author and the inaugural Henry & Amelia Nasrallah Endowed Professor and Director of Geriatric Psychiatry at Saint Louis University George T. Grossberg, M.D., and colleagues shared the results of a national clinical trial. They discovered that REXULTI, also called brexpiprazole, significantly reduced agitation in patients with Alzheimer’s disease and was well tolerated with few side effects.
George Grossberg, M.D. Photo by Sarah Conroy.
Earlier this year, brexpiprazole became the first FDA-approved treatment of agitation-associated Alzheimer’s dementia.
Of the 6.7 million people 65 and older in the US with Alzheimer’s dementia, multiple studies show that about half or more develop agitation.
Agitation associated with Alzheimer’s dementia may include activities like restlessness or more aggressive behavior, like screaming, destroying objects or fighting. Frequent and severe behavioral symptoms can be extremely distressing to the person with Alzheimer’s disease, as well as their families and caregivers.
Antipsychotic drugs are commonly prescribed “off-label” to treat symptoms like aggression and agitation. While these antipsychotics seem to show a modest benefit in treating aggression in the short term, they have adverse effects and other health risks that limit their use over more extended periods.
“When patients with Alzheimer’s dementia develop agitation symptoms, they can become increasingly difficult to manage,” said Grossberg, who is also director of geriatric psychiatry at SLU. “I’m encouraged by the findings of this study which show that brexpiprazole is an effective and well-tolerated medication that can treat the often-debilitating symptoms of agitation associated with dementia due to Alzheimer’s disease.”
In the multicenter Phase 3 clinical trial, researchers evaluated the efficacy and safety of brexpiprazole, a medication used for the treatment of major depressive disorder and schizophrenia, for patients with agitation associated with Alzheimer’s.
The clinical trial was a 12-week, double-blind, placebo-controlled, fixed-dose, parallel-arm trial that enrolled 345 participants at 123 clinical trial sites in Europe and the United States.
Investigators enrolled participants between the ages of 55 to 90 with a diagnosis of probable Alzheimer’s disease and clinically significant symptoms of agitation who lived in a care facility or community-based setting.
Participants were randomly assigned to receive the study drug or a placebo. To participate in the clinical trial, participants had to be stable and have a caregiver who could comply with the study procedures.
“It can be extremely challenging to care for patients with Alzheimer’s disease,” said Grossberg. “Having new medications to help patients who are suffering will enormously benefit patients, healthcare providers, and those caring for their loved ones.”
The clinical trial was supported by Otsuka Pharmaceutical Development & Commercialization and H. Lundbeck.
For more information about the trial, visit ClinicalTrials.gov. The study’s Clinical Trials Identifier is NCT03548584.
Latest Newslink
- With $5 Million HRSA Geriatrics Grant, SLU Prepares Workforce to Care for Older AdultsA new grant will extend 30 years of geriatrics-related funding to Saint Louis University clinicians and researchers.
- SLU History Professor Receives Fulbright Specialist Award to Create Digital Tool Focusing on Gaelic IrelandThomas Finan, Ph.D., associate professor of history at Saint Louis University, has received a Fulbright Specialist Award. He will work with colleagues at the University of Galway to create a joint database of archaeological and historical research focusing on Gaelic Ireland.
- Don't Let that Cookie Crumble: SSE Teams Build, Test Gingerbread HousesTeams of students, faculty and staff in Saint Louis University's School of Science and Engineering recently put their engineering skills to work for a December Innovation Challenge. The teams built gingerbread houses designed to stand up during a weight-loading competition.
- Dr. Edward J. Feser Named 34th President of Saint Louis UniversityFeser, a Roman Catholic, Jesuit-educated leader in higher education, will assume the SLU presidency on July 1, 2025. Feser currently serves as the provost and executive vice president of Oregon State University (OSU), a land-grant institution with more than 38,000 students, a $1.8 billion budget and $480 million annually in externally funded research.
- SLU's Newest Alums Cheered at Commencement CeremonySaturday morning, hundreds of students walked across the stage at Chaifetz Arena and joined the Billiken alumni family. Saint Louis University celebrated its Midyear Commencement on Saturday, Dec. 14, In front of a packed crowd of family members, friends, and loved ones. Those in attendance and watching at home saw the newest graduates of SLU celebrated.
- Amy E. Wright Receives Honorable Mention for MLA's Katherine Singer Kovacs PrizeSaint Louis University's Amy E. Wright, Ph.D., received an honorable mention from the Modern Language Association of America (MLA) for the Katherine Singer Kovacs Prize for an outstanding book published in English or Spanish in the field of Latin American and Spanish literature and cultures. Wright, a professor of Hispanic Studies at SLU, received the honor for her book Serial Mexico: Storytelling across Media, from Nationhood to Now, published in 2023 by Vanderbilt University Press.
